GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » PS Ratio

NurExone Biologic (FRA:J90) PS Ratio : (As of Apr. 10, 2025)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NurExone Biologic's share price is €0.432. NurExone Biologic's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00. Hence, NurExone Biologic's PS Ratio for today is .

The historical rank and industry rank for NurExone Biologic's PS Ratio or its related term are showing as below:

FRA:J90's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 7.815
* Ranked among companies with meaningful PS Ratio only.

NurExone Biologic's Revenue per Sharefor the three months ended in Sep. 2024 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00.

Back to Basics: PS Ratio


NurExone Biologic PS Ratio Historical Data

The historical data trend for NurExone Biologic's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic PS Ratio Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23
PS Ratio
- - -

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NurExone Biologic's PS Ratio

For the Biotechnology subindustry, NurExone Biologic's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's PS Ratio distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's PS Ratio falls into.


;
;

NurExone Biologic PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

NurExone Biologic's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.432/0
=

NurExone Biologic's Share Price of today is €0.432.
NurExone Biologic's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


NurExone Biologic  (FRA:J90) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


NurExone Biologic PS Ratio Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

NurExone Biologic Headlines

No Headlines